Six (or More) Drugs in Search of a Mechanism: DNA Methyltransferase and Histone Deacetylase Inhibitors in the Treatment of Myelodysplastic Syndromes

By Gore Steven D.  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 4, Iss. 1, 2006-01 ,pp. : 83-90

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Development of DNA Methyltransferase Inhibitors for the Treatment of Neoplastic Diseases

By  

Current Medicinal Chemistry, Vol. 16, Iss. 17, 2009-06 ,pp. : 2075-2085

Bentham Science Publishers

Access to resources Recommend Favorite

Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy

By  

Hematological Oncology (Electronic), Vol. 33, Iss. 2, 2015-06 ,pp. : 57-66

John Wiley & Sons Inc

Access to resources Recommend Favorite

Lenalidomide for Treatment of Myelodysplastic Syndromes

By  

Current Pharmaceutical Design, Vol. 18, Iss. 22, 2012-07 ,pp. : 3198-3203

Bentham Science Publishers

Access to resources Recommend Favorite

5-Azacytidine for the treatment of myelodysplastic syndromes

By Krawczyk Janusz   Keane Niamh   Freeman Ciara Louise   Swords Ronan   O'Dwyer Michael   Giles Francis J  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 9, 2013-06 ,pp. : 1255-1268

Informa Healthcare

Access to resources Recommend Favorite